Aprea Therapeutics (APRE) Competitors $1.89 -0.04 (-2.07%) Closing price 04:00 PM EasternExtended Trading$1.83 -0.06 (-3.39%) As of 06:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock APRE vs. CGTX, KALA, BDRX, AKTX, TELO, COEP, HYPD, OKUR, MAAQ, and KZRShould you be buying Aprea Therapeutics stock or one of its competitors? The main competitors of Aprea Therapeutics include Cognition Therapeutics (CGTX), KALA BIO (KALA), Biodexa Pharmaceuticals (BDRX), Akari Therapeutics (AKTX), Telomir Pharmaceuticals (TELO), Coeptis Therapeutics (COEP), Hyperion DeFi (HYPD), OnKure Therapeutics (OKUR), Mana Capital Acquisition (MAAQ), and Kezar Life Sciences (KZR). These companies are all part of the "pharmaceutical products" industry. Aprea Therapeutics vs. Its Competitors Cognition Therapeutics KALA BIO Biodexa Pharmaceuticals Akari Therapeutics Telomir Pharmaceuticals Coeptis Therapeutics Hyperion DeFi OnKure Therapeutics Mana Capital Acquisition Kezar Life Sciences Aprea Therapeutics (NASDAQ:APRE) and Cognition Therapeutics (NASDAQ:CGTX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, media sentiment, valuation, profitability and analyst recommendations. Do insiders and institutionals hold more shares of APRE or CGTX? 34.2% of Aprea Therapeutics shares are held by institutional investors. Comparatively, 43.4% of Cognition Therapeutics shares are held by institutional investors. 13.6% of Aprea Therapeutics shares are held by insiders. Comparatively, 14.4% of Cognition Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Is APRE or CGTX more profitable? Cognition Therapeutics has a net margin of 0.00% compared to Aprea Therapeutics' net margin of -1,095.02%. Aprea Therapeutics' return on equity of -68.39% beat Cognition Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Aprea Therapeutics-1,095.02% -68.39% -55.74% Cognition Therapeutics N/A -194.42%-115.14% Which has preferable valuation and earnings, APRE or CGTX? Aprea Therapeutics has higher revenue and earnings than Cognition Therapeutics. Cognition Therapeutics is trading at a lower price-to-earnings ratio than Aprea Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAprea Therapeutics$1.50M6.97-$12.96M-$2.37-0.80Cognition TherapeuticsN/AN/A-$33.97M-$0.74-1.14 Does the media favor APRE or CGTX? In the previous week, Cognition Therapeutics had 1 more articles in the media than Aprea Therapeutics. MarketBeat recorded 2 mentions for Cognition Therapeutics and 1 mentions for Aprea Therapeutics. Aprea Therapeutics' average media sentiment score of 1.89 beat Cognition Therapeutics' score of 0.93 indicating that Aprea Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Aprea Therapeutics Very Positive Cognition Therapeutics Positive Do analysts rate APRE or CGTX? Aprea Therapeutics currently has a consensus price target of $15.50, suggesting a potential upside of 720.11%. Cognition Therapeutics has a consensus price target of $2.83, suggesting a potential upside of 237.30%. Given Aprea Therapeutics' higher probable upside, analysts plainly believe Aprea Therapeutics is more favorable than Cognition Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aprea Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Cognition Therapeutics 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has more volatility & risk, APRE or CGTX? Aprea Therapeutics has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500. Comparatively, Cognition Therapeutics has a beta of 0.88, indicating that its share price is 12% less volatile than the S&P 500. SummaryAprea Therapeutics beats Cognition Therapeutics on 8 of the 15 factors compared between the two stocks. Get Aprea Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for APRE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding APRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APRE vs. The Competition Export to ExcelMetricAprea TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.68M$3.07B$5.70B$9.51BDividend YieldN/A2.36%4.69%4.01%P/E Ratio-0.8021.0428.0720.05Price / Sales6.97284.46448.5799.42Price / CashN/A42.7636.2258.56Price / Book0.538.378.665.87Net Income-$12.96M-$55.19M$3.25B$258.55M7 Day Performance13.86%5.89%4.20%2.23%1 Month Performance5.00%17.63%10.82%12.76%1 Year Performance-51.04%5.09%34.70%19.36% Aprea Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APREAprea Therapeutics2.922 of 5 stars$1.89-2.1%$15.50+720.1%-50.1%$10.68M$1.50M-0.807Positive NewsCGTXCognition Therapeutics2.7768 of 5 stars$0.61+6.6%$2.83+368.3%-53.2%$37.51MN/A-0.8220KALAKALA BIO3.9708 of 5 stars$5.70-2.6%$13.00+128.1%-0.3%$36.77M$3.89M-0.6930BDRXBiodexa Pharmaceuticals0.2905 of 5 stars$0.98+12.1%N/AN/A$35.81M$470K0.0020Positive NewsHigh Trading VolumeAKTXAkari Therapeutics2.6588 of 5 stars$1.11-1.7%N/A-71.9%$35.75MN/A0.009TELOTelomir Pharmaceuticals2.9162 of 5 stars$1.17+0.9%$15.00+1,182.1%-43.7%$34.82MN/A-2.791News CoverageGap DownCOEPCoeptis Therapeutics0.6828 of 5 stars$9.90+4.5%N/A+117.3%$34.79M$62.87K-1.712Positive NewsGap UpHYPDHyperion DeFi1.132 of 5 stars$12.03-9.1%$2.00-83.4%-92.8%$34.65M$60K-0.2140Positive NewsGap UpOKUROnKure Therapeutics3.4043 of 5 stars$2.50flat$32.33+1,193.3%N/A$33.78MN/A-0.48N/APositive NewsMAAQMana Capital AcquisitionN/A$4.15-3.3%N/A+812.7%$33.72MN/A0.001Gap UpKZRKezar Life Sciences4.1969 of 5 stars$4.58+1.6%$39.50+762.4%-32.4%$33.48M$7M-0.4260 Related Companies and Tools Related Companies CGTX Competitors KALA Competitors BDRX Competitors AKTX Competitors TELO Competitors COEP Competitors HYPD Competitors OKUR Competitors MAAQ Competitors KZR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:APRE) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aprea Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aprea Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free APRE Stock Alerts